<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761578</url>
  </required_header>
  <id_info>
    <org_study_id>ARTDIVA</org_study_id>
    <nct_id>NCT01761578</nct_id>
  </id_info>
  <brief_title>ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent</brief_title>
  <official_title>First in Man Safety Evaluation of the ART18Z Bioresorbable Stent for the Treatment of Single de Novo Lesion of a Native Coronary Artery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arterial Remodeling Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arterial Remodeling Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicentre, open labeled, single arm, first in man interventional
      investigation aims to evaluate the safety of the ART18Z bioresorbable stent for the treatment
      of patients with single de novo lesion of a native coronary artery with mandatory balloon
      predilatation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE rate</measure>
    <time_frame>at 6 months</time_frame>
    <description>Major Adverse Cardiac Event is defined as death, MI (Myocardial Infarction) or any TLR (Target Lesion Revascularization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Performances (Device/Procedure Success)</measure>
    <time_frame>Procedure and post-procedure up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>at 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven TVF, TLR, TVR</measure>
    <time_frame>at 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Angiographic binary restenosis</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Angiographic in-stent Late Lumen Loss</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stent coverage by OCT</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the neointima by OCT</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>ART18Z Bioresorbable stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ART18Z Bioresorbable stent</intervention_name>
    <description>The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.</description>
    <arm_group_label>ART18Z Bioresorbable stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility:

        - Healthy voluntary and women of child-bearing potential are not accepted

        Inclusion Criteria:

        Angiographic Inclusion Criteria:

        Target lesion must meet all of the following criteria

          -  Single vessel lesion

          -  De novo lesion

          -  Located in a native coronary artery with visually estimated nominal artery diameter of
             2.8 to 3.2 mm

          -  Length ≤ 8 mm visually estimated

          -  Located in a major artery or branch with a visually estimated stenosis &gt;50% and &lt;100%
             with a TIMI flow ≥1

        General Inclusion Criteria:

        Patient profile:

          -  Patient is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving the ART18Z Bioresorbable Stent.

          -  Patient provides written informed consent approved by the EC prior to any clinical
             investigation related procedure

          -  Patient must agree to undergo all clinical investigation plan - required clinical
             follow-up visits, QCA, OCT

          -  Patient must agree not to participate in any other clinical investigation for a period
             of 3 years following the procedure

          -  a social security number is required, otherwise patients cannot be included in the
             trial.

        Clinical profile:

          -  Silent ischemia, stable or unstable angina with documented ischemia (stress
             echocardiography, 12-lead ECG, nuclear imaging, bicycle test, Treadmill stress test)

          -  3 months limited clopidogrel treatment must be acceptable in compliance with patient
             health status

          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery

        Exclusion Criteria:

        Angiographic Exclusion Criteria:

          -  Target lesion meets any of the following criteria:

          -  Aorto-ostial location (within 3 mm)

          -  Left main location

          -  located within 3 mm of the origin of the LAD or LCX

          -  Located within an arterial or saphenous vein graft or distal to a diseased (defined as
             vessel irregularity per angiogram and &gt;20% stenosed lesion, by visual estimation)
             arterial or saphenous vein graft

          -  Lesion involving a bifurcation ≥ 1.5 mm in diameter and ostial lesion &gt; 40% stenosed
             by visual estimation or side branch requiring predilatation

          -  Excessive tortuosity proximal to or within the lesion (Extreme angulation (≥ 90%)
             proximal)

          -  Calcification lesion

          -  Restenotic from previous intervention

          -  The target vessel contains visible thrombus

          -  Chronic total occlusion (CTO)

          -  Another clinically significant lesion is located in the same major epicardial vessel
             as the target lesion (including side branches)

          -  Patient has a high probability that a procedure other than pre-dilatation and stenting
             will be required at the time of procedure for treatment of the target vessel (e.g.
             atherectomy, cutting balloon)

          -  Non clinical investigation percutaneous intervention in the target vessel &lt; 6 months
             prior to or if planned to be done within 6 months after the investigational procedure.

          -  Non clinical investigation percutaneous intervention in a non-target vessel &lt; 1 months
             prior to the investigational procedure with TIMI flow = 3 and no evidence of
             dissection at the time of the clinical investigation procedure, or if planned to be
             done within 6 months after the investigational procedure.

        General Exclusion Criteria

          -  Evidence of an acute MI within 3 weeks of the intended investigational procedure

          -  Patient has current unstable arrhythmias

          -  Patient has a known left ventricular ejection fraction (LVEF) &lt; 30%

          -  Patient has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant

          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30
             days prior to or after the procedure

          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus
             etc.)

          -  Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g.,
             heparin, coumadin)

          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and
             bivalirudin, both clopidogrel and ticlopidine, or contrast sensitivity that cannot be
             adequately pre-medicated

          -  Elective surgery is planned within the first 6 months after the procedure that will
             require discontinuing either aspirin or clopidogrel

          -  Patient has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;
             3,000 cells/mm3, or documented or suspected liver disease (including laboratory
             evidence of hepatitis)

          -  Patient has known renal insufficiency with creatine clearance &lt; 40 ml/min or patient
             on dialysis

          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has had a cerebro vascular accident (CVA) or transient ischemic neurological
             attack (TIA) within the past six months

          -  Patient has had a significant GI or urinary bleed within the past six months

          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion

          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the clinical investigation plan, confound the data interpretation
             or is associated with a &lt; 24 months limited life expectancy

          -  Vulnerable population (refer to §6.4)

          -  Patient is already participating in another clinical investigation that has not yet
             reached its primary endpoint

          -  Pregnant or nursing patients and those who plan pregnancy during the clinical
             investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Polyclinique les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.art-stent.com</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable</keyword>
  <keyword>Coronary</keyword>
  <keyword>Stent</keyword>
  <keyword>Vascular Remodeling</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

